Latest news with #Enhertu
Yahoo
11-07-2025
- Business
- Yahoo
Cancer Antibody Drug Conjugates Treatment Market Size Clinical Trials FDA Approved Report
Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research Delhi, July 11, 2025 (GLOBE NEWSWIRE) -- Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales and Clinical Trials Insight 2030 Report Finding & Inclusions: Global Cancer Antibody Drug Conjugates Market: 2020 – 2030 Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030 Approved Cancer Antibody Drug Conjugates: 16 Drugs Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage and Price Analysis Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase Insight On Commercially Approved Antibody Drug Conjugates By Brand Name, Company and Indication Download Report: The global cancer antibody-drug conjugate (ADC) market represents one of the most dynamic and rapidly advancing areas in oncologic therapy. ADCs combine the precision targeting of monoclonal antibodies with potent cytotoxic agents, delivering effective treatment directly to cancer cells while sparing healthy tissue. As of July 2025, nineteen ADCs have been approved worldwide, underscoring both clinical acceptance and regulatory momentum. Key approved ADCs include Enhertu (trastuzumab deruxtecan), which generated over US$ 3.75 billion in 2024 sales, led by its strong performance in HER2-positive cancers. Kadcyla (trastuzumab emtansine) also continues to deliver blockbuster revenue, with approximately US$ 2.3 billion in sales in 2024. Other top-performing ADCs include Adcetris (US$ 1.91 billion), Padcev (US$ 1.59 billion), Trodelvy (US$ 1.32 billion), and Polivy (US$ 1.30 billion). The commercial success of these therapies reflects their differentiated clinical value and growing adoption across multiple oncology indications. The market outlook remains strong, with forecasts projecting the ADC segment to surpass US$ 50 billion by 2030, driven by indication expansion, global market penetration, and sustained innovation. The clinical pipeline features over 500 ADC candidates utilizing diverse payloads, bispecific constructs, and next-generation linker technologies. Trials are being conducted globally, with leadership from US and European pharmaceutical companies and rising activity across the Asia-Pacific region—particularly in China, where domestic ADCs such as Aidixi (disitamab vedotin) have gained approval. Approved ADCs have demonstrated significant impact across different tumor targets. Enhertu and Kadcyla underscore the potential of HER2-directed therapy, while agents like Trodelvy (Trop-2), Polivy (CD79b), and Padcev (Nectin-4) exemplify ADC effectiveness in other solid and hematologic malignancies. Patent protection varies across the field, with many agents maintaining extended market exclusivity through novel payload-linker innovations and optimized delivery mechanisms. The ADC clinical pipeline reveals deep innovation. Over 500 molecules are in development, with trials mapped by company, geography, indication, and phase. This breadth enables stakeholders to track development trends across solid and hematologic cancers, with indications expanding into lung, urothelial, ovarian, and beyond. Company-level insights spotlight R&D activity, with several early-stage ADCs progressing into pivotal trials. Commercially approved ADC brands are profiled thoroughly in our report. Enhertu, Kadcyla, Adcetris, Padcev, Polivy, Trodelvy, and newer agents such as Datroway (datopotamab deruxtecan) and Zynlonta (loncastuximab tesirine) are explored in-depth, analyzing mechanisms, development history, regulatory milestones, and indication-specific adoption. This provides a tactical overview of competitive positioning and licensing trends—especially in Asia-Pacific, where local players are launching biosimilar or region-specific ADCs. Our Global Cancer ADC Market Report delivers a comprehensive, data-driven foundation for stakeholders. It includes sales performance and patent analysis for 19 approved ADCs, pricing strategy insights and dosage regimens, pipeline tracking of 500+ clinical ADCs by indication and trial phase, and brand-by-brand commercial intelligence. This resource empowers pharmaceutical executives, biotech investors, and clinical researchers with the insights needed to navigate a sector poised for exponential growth. As ADC therapy evolves, our report is the strategic compass for development prioritization, portfolio building, and market entry planning—at the frontline of oncology Neeraj Chawla Research Head Kuick Research neeraj@ +91-11-47067990 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
&w=3840&q=100)

First Post
11-07-2025
- Health
- First Post
Major cancer drugs could become cheaper as India considers import duty waiver
The documents show that blockbuster cancer drugs like pembrolizumab (brand Keytruda), osimertinib (brand Tagrisso), and trastuzumab deruxtecan (brand Enhertu), used to treat lung and breast cancer, will be fully exempted from customs duty read more India will likely slash the prices of medicines used to treat critical conditions like HIV Aids and cancer as a government panel has recommended waiving off some customs duties on high-impact drugs. News18 has accessed a document of the proposed cuts in prices that are expected to provide relief to patients with cancer and other chronic diseases. The central government has constituted an interdepartmental committee that has suggested customs duty exemptions and concessions for high-impact medical imports. STORY CONTINUES BELOW THIS AD Established in August 2024 by the Drug Controller General of India (DCGI), the panel is headed by Joint Drug Controller R. Chandrashekar and includes representatives from the Indian Council of Medical Research (ICMR), the Department of Pharmaceuticals, and the Directorate General of Health Services (DGHS). Its goal is to make life-saving treatments, such as those for cancer, rare diseases, organ transplants, and advanced diagnostics, much more affordable for Indian patients. More from Health US faces worst measles outbreak in decades amid falling vaccination rates under Trump Which drugs will get cheaper? The documents show that blockbuster cancer drugs like pembrolizumab (brand Keytruda), osimertinib (brand Tagrisso), and trastuzumab deruxtecan (brand Enhertu), used to treat lung and breast cancer, will be fully exempted from customs duty. These medicines often cost up to lakhs per dose and have remained inaccessible to patients due to the high import burden. Apart from cancer drugs, the committee has also proposed making several other medicines cheaper, including transplant drugs, critical care medicines, and advanced diagnostic kits that are slapped with heavy import duties and have no equivalent in the Indian market. A second category of essential but widely available drugs has been proposed for a reduced import duty of 5 per cent. This list includes hydroxyurea, used to treat cancer and sickle cell anaemia, and low molecular weight heparin, marketed as Enoxaparin, which is commonly used to prevent and treat blood clots and deep vein thrombosis. Therapies also included Along with life-saving drugs, the document also mentions price cuts for medical therapies to treat rare diseases. Customs duty exemptions might be applied on a group of therapies used to treat conditions such as spinal muscular atrophy, cystic fibrosis, Gaucher disease, Fabry disease, lysosomal storage disorders, and hereditary enzyme deficiencies. Many of these therapies, such as gene-based and enzyme replacement treatments, rank among the most expensive drugs globally, with single courses costing several crores. Notable rare disease drugs on the list include Zolgensma, Spinraza, Evrysdi, Cerezyme, and Takhzyro. These medications are extremely costly and largely beyond the reach of most Indian patients. STORY CONTINUES BELOW THIS AD


Business Insider
03-07-2025
- Business
- Business Insider
British Drugs Giant AstraZeneca Pondering Stock Market Shift to the U.S.
Pharmaceutical giant AstraZeneca (AZN), the U.K.'s most valuable company, is considering moving its stock market listing to the U.S. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. U.K. Restrictions Chief Executive Sir Pascal Soriot, as reported by The Times, has spoken privately about his desire to leave the FTSE 100 behind and head stateside. Soriot is said to be concerned about how quickly Europe is falling behind the U.S. and China when it comes to medicine innovation. He is also known to be frustrated by the restrictions on approvals of new drugs and treatments by the state-owned National Institute for Health and Care Excellence, or NICE – such as breast cancer drug Enhertu. AstraZeneca is no stranger to the U.S., which accounts for over 40% of its $54 billion group revenues. It recently ramped up investment there both to escape tariff hits and as a move away from those U.K. and European restrictions. London Loss The loss of the firm, with a market value of around £160 billion, would be a major blow to the London stock market and will likely meet opposition from some shareholders and the U.K. government. It would follow on the heels of other firms shifting their primary listings to the U.S., such as building materials supplier CRH (CRH). 'America is important to its growth strategy and it could become an even bigger cog in the wheel,' said Dan Coatsworth, investment analyst at AJ Bell. 'The CEO seems frustrated at the lack of financial support to open new laboratories and manufacturing facilities in Europe and might see a full U.S. stock listing as a stepping stone to receiving better treatment stateside.' Is AZN a Good Stock to Buy Now?

Rhyl Journal
02-07-2025
- Health
- Rhyl Journal
Breast cancer patients ‘denied life-extending drugs because of unfair system'
Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints. It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition. Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use. According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light. However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating. The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales. In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement. Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system. 'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school. 'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer. 'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system. 'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.' Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer. The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have. 'If a new drug can give me another six months, if it gives me another year, it's worth it. 'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.' Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints. Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one. According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'. It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.' Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now. 'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.' Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected. 'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines. 'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer. 'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer. 'It remains the only breast cancer treatment we have been unable to recommend in seven years.' A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'. 'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added. 'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'


North Wales Chronicle
02-07-2025
- Health
- North Wales Chronicle
Breast cancer patients ‘denied life-extending drugs because of unfair system'
Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints. It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition. Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use. According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light. However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating. The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales. In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement. Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system. 'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school. 'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer. 'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system. 'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.' Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer. The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have. 'If a new drug can give me another six months, if it gives me another year, it's worth it. 'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.' Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints. Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one. According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'. It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.' Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now. 'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.' Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected. 'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines. 'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer. 'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer. 'It remains the only breast cancer treatment we have been unable to recommend in seven years.' A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'. 'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added. 'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'